Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiac Biotech SolutionsCBSC 3-Year RORE % is 0.00 as of Jun. 2025. Among 777 Medical Devices & Instruments companies, Cardiac Biotech Solutions ranks worse than 84.17% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cardiac Biotech Solutions's 3-Year RORE % for the quarter that ended in Jun. 2025 was 0.00%.
The industry rank for Cardiac Biotech Solutions's 3-Year RORE % or its related term are showing as below:
CBSC's 3-Year RORE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -4.03 * Ranked among companies with meaningful 3-Year RORE % only.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cardiac Biotech Solutions 3-Year RORE % Related Terms
Cardiac Biotech Solutions 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBSC vs LUCY, NXGL, MHUAF: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.
Cardiac Biotech Solutions (CBSC) has a 3-Year RORE % of 0.00 as of Jun. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cardiac Biotech Solutions and its competitors. According to the industry distribution chart, Cardiac Biotech Solutions ranks #654 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 84.2%.
Is Cardiac Biotech Solutions' 3-Year RORE % too high?
Cardiac Biotech Solutions' current 3-Year RORE % is 0.00. Based on the distribution chart, Cardiac Biotech Solutions ranks #654 out of 777 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Cardiac Biotech Solutions' 3-Year RORE % compare to LUCY and NXGL?
According to the Medical Devices & Instruments industry distribution chart, Cardiac Biotech Solutions ranks #654 out of 777 companies for 3-Year RORE %. This places Cardiac Biotech Solutions in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current 3-Year RORE % is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
